TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02602093

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Endoscopic Discectomy
Description: Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Microdiscectomy
Description: General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
Study: NCT02484066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VBN
Description: VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VBN
Description: VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
Study: NCT03065777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONE ENDO
Description: single file rotary system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F6 SKYTaper
Description: single file rotary system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProTaper Universal
Description: multi-file rotary system
Study: NCT04146168

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
Study: NCT00981149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo match duloxetine for 6 week period.
Study: NCT03432507

Intervention type: OTHER
Intervention: PCR
Description: PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria

Intervention type: OTHER
Intervention: PCR
Description: PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria
Study: NCT02925897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change and motivational interviewing
Description: nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
Study: NCT04034823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN035
Description: KN035 5 mg/kg s.c. Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg IV loading followed by 6 mg/kg Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2 Q3W IV
Study: NCT01844388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose based eye drop formula
Description: 1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose sodium based eye drop solution
Description: 1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
Study: NCT04012580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-assisted ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
Study: NCT02884388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined nerve block
Description: Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Patients in this group were assigned to receive general anesthesia.
Study: NCT02055898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo (fresh potable water)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo (fresh potable water)
Study: NCT02304900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white implant
Description: 1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yellow implant
Description: 1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye
Study: NCT03371472

Intervention type: DEVICE
Group type: OTHER
Intervention: Visualisation and measuring of paravalvular leak.
Description: Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).

Intervention type: DEVICE
Group type: OTHER
Intervention: Visualisation and measuring of paravalvular leak.
Description: Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).
Study: NCT01030029

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical auricular acupuncture
Description: Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point \[2\]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: P-Stim™ devices were applied without electrical stimulation and acupuncture.
Description: Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
Study: NCT03992079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReCOVER Enhanced Recovery Protocol
Description: The experimental group will receive preemptive pain management before surgery, an opioid-free strategy during surgery, and an opioid-sparing multimodal pain management protocol after surgery.
Study: NCT01507922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoverine
Description: Fenoverine 100mg three times a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timebutine
Description: Timebutine maleate 150mg three times a day for 8 weeks
Study: NCT02649140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vinegar group
Description: Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
Study: NCT00358397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium novyi-NT spores
Study: NCT00756249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vials with solution for IV infusion
Study: NCT01349517

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MIE
Description: The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Three-incision thoracotomy
Description: The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ivor-Lewis esophagectomy
Description: The patients in this group would underwent Ivor-Lewis esophagectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sweet esophagectomy
Description: The patients in this group would underwent Sweet esophagectomy.
Study: NCT00557921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin
Description: (CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix (clopidogrel 75 mg) and aspirin
Description: (CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
Study: NCT00688259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy (ST)
Description: approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Psychosis (CBTp)
Description: approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
Study: NCT03153514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab i.v.~\[Day 0 = day of stem cell transplant\]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)
Study: NCT00965081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD po at the same time each day for 12 weeks
Study: NCT02060435

Intervention type: OTHER
Intervention: EBER
Description: EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
Study: NCT04713280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary posterior dento-alveolar intrusion
Description: Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary posterior dento-alveolar intrusion
Description: Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion
Study: NCT02004353

Intervention type: DEVICE
Intervention: Cochlear® Hearing Implants
Description: Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
Study: NCT01566253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen, ketoprofen, morphine
Description: Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
Study: NCT02418871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluidVision AIOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject. An improved injector system was used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Performed using standard microsurgical techniques
Study: NCT01147666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.
Study: NCT01566253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, ketoprofen,morphine
Description: Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
Study: NCT01350739

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraumbilical incision
Description: vertical, intraumbilical incision

Intervention type: PROCEDURE
Group type: OTHER
Intervention: infraumbilical incision
Description: incision at the inferior boarder of the umbilicus, circular
Study: NCT01147666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin Alfa will be administered per dose and schedule specified in the arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin Alfa will be administered per dose and schedule specified in the arms.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to roxadustat will be administered per schedule specified in the arm.
Study: NCT00730977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dry powder inhaled mannitol
Description: single doses of 40 mg, 70 mg and 100 mg
Study: NCT03596827

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: E. coli strain E1392-75-2A dose 1E10 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A dose 1E9 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A dose 1E8 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A dose 1E7 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
Study: NCT01303029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine+erlotinib
Description: Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
Study: NCT03596827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A dose 1E6 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
Study: NCT03701139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior capsulotomy
Description: After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser capsulotomy
Description: A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
Study: NCT02558517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone discontinuation
Description: randomization
Study: NCT02917135

Intervention type: DEVICE
Intervention: Angel® Catheter
Description: The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.~The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein.
Study: NCT01712126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan and Hydrochlorothiazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avalide
Study: NCT02432326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
Study: NCT01303029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+erlotinib+capecitabine
Description: Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .